Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

Video

In Partnership With:

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Michael Wang, MD, professor, Departments of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolution of ibrutinib (Imbruvica) in the treatment landscape of mantle cell lymphoma (MCL).

Ibrutinib has been utilized for many years following its approval for relapsed MCL in November 2013, Wang explains. Moreover, Wang began implementing the agent in practice prior to its approval, he adds. Additionally, Wang says he has studied Ibrutinib and other agents, specifically regarding the mechanism of resistance caused by ibrutinib and other BTK inhibitors.

Other clinical trials have explored the utility of ibrutinib in MCL, further increasing its potential within the space, Wang continues. The agent has been utilized in various relapse settings of MCL, Wang concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
A panel of 4 experts on hematologic malignancies
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.